Bristol-Myers Squibb Co (XSWX:BMY) Cyclically Adjusted Revenue per Share: CHF17.93 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BMY Bristol-Myers Squibb Co XSWX:BMY
71 GF Score
Price CHF54.34
GF Value CHF45.71
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share?

Bristol-Myers Squibb Co XSWX:BMY 71 Cyclically Adjusted Revenue per Share is CHF17.93 as of Jun. 2026. GuruFocus rates XSWX:BMY with a GF Score™ of 71/100 and a GF Value™ of CHF45.71 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bristol-Myers Squibb Co's adjusted revenue per share for the three months ended in Jun. 2026 was CHF5.063. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF17.93 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bristol-Myers Squibb Co's average Cyclically Adjusted Revenue Growth Rate was 8.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 7.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Bristol-Myers Squibb Co was 10.70% per year. The lowest was -1.00% per year. And the median was 4.50% per year.

As of today (2026-09-07), Bristol-Myers Squibb Co's current stock price is CHF54.34. Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was CHF17.93. Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio of today is 3.03.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bristol-Myers Squibb Co was 6.08. The lowest was 2.08. And the median was 4.37.


Bristol-Myers Squibb Co  (XSWX:BMY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=54.34/17.93
=3.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bristol-Myers Squibb Co was 6.08. The lowest was 2.08. And the median was 4.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Related Terms


Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bristol-Myers Squibb Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 17.24 17.93

XSWX:BMY vs PFE, GILD, AMGN: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Cyclically Adjusted PS Ratio falls into.


XSWX:BMY
71GF Score
Bristol-Myers Squibb Co XSWX:BMY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bristol-Myers Squibb Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.063/333.9520*333.9520
=5.063

Current CPI (Jun. 2026) = 333.9520.

Bristol-Myers Squibb Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.853 241.428 3.946
201612 3.176 241.432 4.393
201703 2.954 243.801 4.046
201706 3.018 244.955 4.114
201709 3.074 246.819 4.159
201712 3.273 246.524 4.434
201803 3.002 249.554 4.017
201806 3.452 251.989 4.575
201809 3.368 252.439 4.456
201812 3.619 251.233 4.811
201903 3.618 254.202 4.753
201906 3.786 256.143 4.936
201909 3.642 256.759 4.737
201912 4.024 256.974 5.229
202003 4.580 258.115 5.926
202006 4.258 257.797 5.516
202009 4.211 260.280 5.403
202012 4.366 260.474 5.598
202103 4.546 264.877 5.732
202106 4.718 271.696 5.799
202109 4.782 274.310 5.822
202112 4.970 278.802 5.953
202203 5.003 287.504 5.811
202206 5.367 296.311 6.049
202209 5.083 296.808 5.719
202212 5.007 296.797 5.634
202303 4.966 301.836 5.494
202306 4.809 305.109 5.264
202309 4.780 307.789 5.186
202312 4.882 306.746 5.315
202403 5.212 312.332 5.573
202406 5.375 314.175 5.713
202409 4.961 315.301 5.254
202412 5.421 315.605 5.736
202503 4.852 319.799 5.067
202506 4.896 322.561 5.069
202509 4.772 324.800 4.906
202512 4.887 324.054 5.036
202603 4.419 330.213 4.469
202606 5.063 333.952 5.063

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of CHF17.93 mean?
Bristol-Myers Squibb Co (XSWX:BMY) has a Cyclically Adjusted Revenue per Share of CHF17.93 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors.
Is Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share too high?
Bristol-Myers Squibb Co's current Cyclically Adjusted Revenue per Share is CHF17.93. Overall, Bristol-Myers Squibb Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share compare to PFE and GILD?
Bristol-Myers Squibb Co's Cyclically Adjusted Revenue per Share of CHF17.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Cyclically Adjusted Revenue per Share is CHF17.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (XSWX:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF45.71, compared to a current price of CHF54.34 — trading 18.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is CHF17.93. Bristol-Myers Squibb Co's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current Cyclically Adjusted Revenue per Share is CHF17.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of CHF54.34 is trading 18.9% above its estimated GF Value™ of CHF45.71. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for XSWX:BMY:

  • Cyclically Adjusted Revenue per Share: CHF17.93
  • GF Value™: CHF45.71 vs. price of CHF54.34 (18.9% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
71GF Score

Get the complete analysis for XSWX:BMY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.34
Price
CHF45.71
GF Value